HUTCHMED (China) Limited (AIM:HCM)
181.54
-0.46 (-0.25%)
May 19, 2026, 11:34 AM GMT
HUTCHMED (China) Revenue
In the year 2025, HUTCHMED (China) had annual revenue of $548.51M USD, down -12.96%. HUTCHMED (China) had revenue of $270.84M in the half year ending December 31, 2025, a decrease of -11.24%.
Revenue
$548.51M
Revenue Growth
-12.96%
P/S Ratio
3.84
Revenue / Employee
$305.41K
Employees
1,796
Market Cap
1.56B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 548.51M | -81.69M | -12.96% |
| Dec 31, 2024 | 630.20M | -207.80M | -24.80% |
| Dec 31, 2023 | 838.00M | 411.59M | 96.52% |
| Dec 31, 2022 | 426.41M | 70.28M | 19.73% |
| Dec 31, 2021 | 356.13M | 128.15M | 56.21% |
| Dec 31, 2020 | 227.98M | 23.09M | 11.27% |
| Dec 31, 2019 | 204.89M | -9.22M | -4.31% |
| Dec 31, 2018 | 214.11M | -27.09M | -11.23% |
| Dec 31, 2017 | 241.20M | 25.12M | 11.63% |
| Dec 31, 2016 | 216.08M | 37.88M | 21.25% |
| Dec 31, 2015 | 178.20M | 90.87M | 104.06% |
| Dec 31, 2014 | 87.33M | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
| Dec 31, 2006 | - | - | - |
| Dec 31, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Haleon | 11.03B |
| Hikma Pharmaceuticals | 2.49B |
| ECO Animal Health Group | 85.81M |
| Allergy Therapeutics | 57.29M |
| Shield Therapeutics | 36.93M |
| Venture Life Group | 35.17M |
| Provexis | 871.27K |
| Chill Brands Group | 370.50K |
HUTCHMED (China) News
- 21 hours ago - Award-winning HR Software Vendor HiBob Named an ISG 2026 Vendor of Excellence for Human Capital Management (HCM) Platforms - GlobeNewsWire
- 5 days ago - Chengdu Origen and Vanotech Announce KHN921 Investigational New Drug application clearance by the US FDA for the treatment of hypertrophic cardiomyopathy (HCM) associated with MYBPC3 mutations - GlobeNewsWire
- 19 days ago - HCM Receives Priority Review for New Drug Application in China - GuruFocus
- 20 days ago - Hutchmed says NDA for sovleplenib accepted in China - TheFly
- 20 days ago - HUTCHMED (China) Transcript: Deutsche Bank ADR Virtual Investor Conference - Transcripts
- 21 days ago - HUTCHMED (China) Ltd (HCM) Shares Fall 3.9% -- GF Value Says Still Overvalued - GuruFocus
- 5 weeks ago - HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026 - GlobeNewsWire
- 2 months ago - HUTCHMED Initiates And Doses First Patient In Phase III Trial Of HMPL-760 For R/R DLBC Lymphoma - Nasdaq